Neisseria meningitidis group C polysaccharide-tetanus toxoid conjugate was prepared to obtain the polysaccharide component in a thymus-dependent form and to preserve the immunogenic properties of the tetanus toxoid component. Biochemical and immunochemical analyses of this conjugate revealed that (i) it was composed of equal amounts of polysaccharide and protein; (ii) the antigenic activity of the polysaccharide component was greatly reduced; (iii) it contained about 10o free polysaccharide; (iv) the composition was not homogeneous; and (v) only 5% of the tetanus toxoid component was present at the surface of the conjugate molecules. In this study, the influence of these characteristics on the antibody response to both components in mice was investigated. The doseresponse relationship, the persistence of antibodies, a possible antigenic competition, and the specificities of the antibodies induced were also studied. Our data suggest that the conjugate behaves as a pronounced thymus-dependent antigen, that the tetanus toxoid component is more immunogenic at lower dosages (0.8 and 20 ng) than equivalent doses of tetanus vaccine, that the presence of free polysaccharide does not influence the induction of antibodies to polysaccharide by the conjugate, and that no antibodies to new structures in the conjugate are induced. These characteristics favor the application of this conjugate as a vaccine for human use.
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Purified meningococcal groups A, C, W135, Y, and Z' (29E) induce protective bactericidal antibodies in humans and mice (9, 10, 17, 18, 39) . These antibodies exert their protective effect by initiating complement-dependent bacteriolysis and opsonization (15, 16, 26) .
It is well known that no helper thymus-derived cells are involved in the immune response to purified polysaccharides from encapsulated bacteria in mice (5); most likely they are not involved in humans, either (6) . As a consequence, they only induce an immunoglobulin M (IgM) antibody response in mice (3, 8, 9) and uncommitted individuals, e.g., very young children (22) . Moreover, a second dose will not result in a booster reaction (4, 17) . Such (42, 43) . The characteristics of the group Z' polysaccharide were in accordance with those described by Tiesjema and Beuvery (39) . Tetanus toxoid was purified bulk material used for vaccine production. Adsorbed diphtheria-tetanusinactivated poliomyelitis vaccine, produced by our institute, was used as tetanus vaccine.
Conjugation of polysaccharides with tetanus toxoid.
The conjugation of group W135, Y, and Z' polysaccharides with tetanus toxoid was performed as described previously (9) . The gel filtration of tetanus toxoid and the addition of ethanolamine were omitted. For the preparation of the group C polysaccharide-tetanus toxoid conjugate, however, ethanolamine was added (7) .
Chemical assays. The polysaccharide contents of the group C, W135, and Y conjugates and that of the group Z' conjugate were determined by the methods of Svennerholm (35) and Osborne (21) , respectively, with the purified polysaccharides as standards. The assay for protein was performed as described (9) . All b By one dose of group C polysaccharide-tetanus toxoid conjugate.
c By one dose of tetanus vaccine.
the isotype distribution of the antibodies, the four antiIgG-enzyme conjugates were diluted in such a way that they gave the same ODs.
(ii) Assay of antibodies to the polysaccharide, tetanus toxoid, and group C polysaccharide-tetanus toxoid conjugate. The assay of antibodies against group C polysaccharide and tetanus toxoid is described elsewhere (9, 40) . The assay of antibodies to the conjugate was done essentially by the same method as the antipolysaccharide assay. Instead of group C polysaccharide, the corresponding amount of conjugate was added.
The IgG isotypes of the anti-polysaccharide and anti-tetanus toxoid antibodies have been determined by enzyme-linked immunosorbent assay (ELISA) with the specific anti-IgG-enzyme conjugates. The serum samples were tested in a suitable dilution, giving an OD in the linear portion of the dilution-OD curve. The results have been converted to the 1/100 dilution of the samples.
The antibody levels which are presented in all tables (except Table 1 Inhomogeneity of the composition of the conjugate and consequences of the presence of free polysaccharide. CsCl equilibrium density gradient analysis of the conjugate revealed that its composition was not homogeneous (7). The four gradient fractions and group C polysaccharidetetanus toxoid conjugate were injected into mice. Table 3 shows the tetanus toxoid-to-polysaccharide ratios of the fractions, the N-acetylneuraminic acid recoveries, and their responses in mice. The IgG responses to group C polysaccharide and tetanus toxoid were positively related with the tetanus toxoid-to-polysaccharide ratio. Fraction 7, in which no tetanus toxoid could be detected, did not induce IgG antibodies. From Table 3 it can also be concluded that the portion of this fraction in the conjugate was about 10%. The influence of the presence of free polysaccharide in the conjugate on the immune response was studied by mixing conjugate and group C polysaccharide treated with coupling reagent (7) in ratios of 1:4 and 1:16. The total amount of group C polysaccharide in the mixtures was kept constant. The two mixtures and the corresponding amounts of free conjugate and treated group C polysaccharide were administered to mice. The levels induced by the two mixtures (Table 4 ) did not differ significantly (level of significance, 0.05) from those induced by the corresponding doses of conjugate. The levels were clearly dose dependent. As could be expected, treated group C polysaccharide did not induce IgG antibodies.
Effect of dose and persistence of antibodies. Groups of mice were injected twice with 0.8, 20, and 500 ng of conjugate and tetanus vaccine. The antibody assays were done in pooled serum samples collected after 2, 4, 7, 10, 12, 14, and 20 weeks. The time courses of the IgG antibody levels to group C polysaccharide and tetanus toxoid are given in Fig. 1 and 2 of mice were injected with 0.8, 20, and 500 ng of tetanus vaccine. Three other groups were used as controls. After 10 weeks, the three groups of primed mice and the control groups were injected with the three corresponding doses of conjugate. The same doses were also injected into the control groups. The serum samples taken after 4 weeks were assayed for IgG antibodies against group C polysaccharide. Figure 3 shows bovine serum albumin (9) . Both conjugates (20-and 500-ng amounts) were injected twice into groups of mice. Serum samples collected 4 weeks after both injections were assayed for antibodies against group C polysaccharide (Fig.  4) . The group C polysaccharide-tetanus toxoid conjugate clearly induced higher antibody levels after both injections than the group C polysaccharide-bovine serum albumin conjugate did.
Interference of the antibody response to both components of the conjugate after inijection of a mixture of four tetanus toxoid-containing conjugates. Four groups of mice were injected twice with group C polysaccharide-tetanus toxoid conjugate, a mixture of conjugates of four polysaccharide (group C, group W135, group Y, and group Z') with tetanus toxoid, group C polysac- 41, 1983 on October 28, 2017 by guest http://iai.asm.org/ 
DISCUSSION
Meningococcal group C polysaccharide vaccine has proved to be effective in stopping epidemics due to group C organisms (17) . The vaccine, however, has two drawbacks. First, children younger than 2 years cannot be protected directly (36) . Second, the persistence of antibodies in the older age group is rather variable (6) . These characteristics may be associated with the thymus-independent nature of the polysaccharide as an immunogen. The antibody response to the polysaccharide can be made thymus dependent by conjugation with thymusdependent carriers (1, 7-9, 13, 20, 29, 30, 33, 34 Our yields (7, 9) are about 30 times higher than that of their conjugation procedure. Four different IgG isotypes in mice have been described (23) . The isotypes of antibodies induced by an antigen may be related to its thymus dependence (12, 24, 31, 32) . Tetanus vaccine and the tetanus component of the conjugate induced mainly IgGl antibodies, which is a typical response of a thymus-dependent antigen. The lack of isotype specificity of the anti-IgGlenzyme conjugate (Table 1) does not affect this conclusion. The polysaccharide component of the conjugate exhibited almost the same response. The only difference was an additional small amount of IgG3 antibodies, generally induced by branched polysaccharides (31, 32) . A similar response was described by Stein et al. (34) after injection with the thymus-dependent analog of B512 dextran. Previous data (9) (9) . On a weight basis, a dose of 20 ng corresponds to the human dose of group C polysaccharide and tetanus vaccines. At this dose and also at a dose of 0.8 ng, the tetanus toxoid component of the conjugate seems to be more immunogenic than tetanus vaccine in corresponding dosages. The secondary injection of both components gave excellent booster effects, which also indicates that helper T cells are involved in the immune response. However, like Anderson (1), we were not able to show an effect of carrier priming by tetanus vaccine on the response to the polysaccharide component of the conjugate.
The nature of the carrier protein seems to have great influence on the response to the polysaccharide component. Despite its higher protein content (9), the bovine serum albumin conjugate had a lower potential for inducing antibodies to group C polysaccharide. This lower potential may be due to a lower availability of the protein on the surfaces of the conjugate molecules. A similar observation was made by Chu et al. (13) . They found differences in the influence of carrier proteins.
After injection of a mixture of four polysaccharide-tetanus toxoid conjugates, including the group C polysaccharide conjugate, no antigenic (intermolecular) competition (25, 37, 38) in the response to group C polysaccharide and tetanus toxoid was seen, although the same carrier protein was used (27) . This may be ascribed to the rather low dose of conjugates used in our experiment. In this respect too our data agree with those of Chu et al. (13) .
Contrary to the results of Jennings and Lugowsky (20) , we were able to remove all antibodies to the conjugate by absorption with a mixture of group C polysaccharide and tetanus toxoid. This means that no antibodies have been induced to new structures in the conjugate originating from the conjugation of the two components by the coupling reagent. The non-immunogenicity of new structures at the linkage between both components of the conjugate may be another advantage of our conjugation procedure. 
